source
- Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drugIn the wake of its high-profile setback in heart disease late last week, Novartis really needed a win. It didn’t get one. The Swiss pharma said Tuesday that in a late-stage ...Endpoints · 1h ago↗ source
- Novartis reports Phase 3 pelacarsen trial fails to improve cardiovascular outcomesNovartis said its late-stage Phase 3 trial of the antisense drug pelacarsen did not show a benefit in reducing major cardiovascular events compared with placebo. The result adds to a recent string…